Home
Drugs
Lenvatinib
Clinical Trials

Clinical Trials Related to Lenvatinib

Related studies linked through entity extraction aliases.

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Status: RECRUITING
Phase: PHASE1/PHASE2

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

Status: RECRUITING
Phase: N/A

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）

Status: RECRUITING
Phase: PHASE2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Status: RECRUITING
Phase: PHASE2

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Status: RECRUITING
Phase: PHASE1/PHASE2

Neoantigen Derived DCs as Cancer Treatment

Status: RECRUITING
Phase: PHASE1

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Status: RECRUITING
Phase: PHASE2

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Status: UNKNOWN
Phase: PHASE1/PHASE2

SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)

Status: NOT_YET_RECRUITING
Phase: PHASE3

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Status: RECRUITING
Phase: N/A

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Status: RECRUITING
Phase: N/A

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Status: RECRUITING
Phase: PHASE1

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Status: NOT_YET_RECRUITING
Phase: NA

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Status: RECRUITING
Phase: PHASE3

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Status: RECRUITING
Phase: PHASE1

Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT

Status: WITHDRAWN
Phase: NA

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Status: RECRUITING
Phase: PHASE2

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Status: UNKNOWN
Phase: PHASE2